XML 11 R4.htm IDEA: XBRL DOCUMENT
v3.21.4

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) | Share capital [Member] | Subscriptions receivable [Member] | Subscriptions received [Member] | Reserves [Member] | Deficit [Member] | Total
--- | --- | --- | --- | --- | --- | ---
Balance at May. 31, 2019 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0
Balance (shares) at May. 31, 2019 | 0 |  |  |  |  |
Private placement | $ 203,980 | (81,980) | 0 | 0 | 0 | 122,000
Private placement (shares) | 4,079,600 |  |  |  |  |
Acquisition of intangible assets | $ 2,000 | 0 | 0 | 0 | 0 | 2,000
Acquisition of intangible asset (shares) | 40,000 |  |  |  |  |
Net loss | $ 0 | 0 | 0 | 0 | (78,717) | (78,717)
Balance at Sep. 30, 2019 | $ 205,980 | (81,980) | 0 | 0 | (78,717) | 45,283
Balance (shares) at Sep. 30, 2019 | 4,119,600 |  |  |  |  |
Private placement | $ 779,924 | 80,980 | 147,426 | 0 | 0 | 1,008,330
Private placement (shares) | 623,941 |  |  |  |  |
Share issue costs | $ (5,243) | 0 | 0 | 0 | 0 | (5,243)
Share-based compensation | 0 | 0 | 0 | 161,300 | 0 | 161,300
Net loss | 0 | 0 | 0 | 0 | (480,377) | (480,377)
Balance at Sep. 30, 2020 | $ 980,661 | (1,000) | 147,426 | 161,300 | (559,094) | 729,293
Balance (shares) at Sep. 30, 2020 | 4,743,541 |  |  |  |  |
Private placement | $ 27,924,936 | (32,684) | (147,426) | 0 | 0 | 27,744,826
Private placement (shares) | 5,049,021 |  |  |  |  |
Finder's fees - cash | $ (1,516,317) | 0 | 0 | 0 | 0 | (1,516,317)
Finder's fees - broker warrants | (521,000) | 0 | 0 | 521,000 | 0 | 0
Finder's fees - share options | (2,140) | 0 | 0 | 2,140 | 0 | 0
Debt settlement with shares | 18,500 | 0 | 0 | 0 | 0 | 18,500
Share issue costs | $ (290,309) | 0 | 0 | 0 | 0 | (290,309)
Debt settlement with shares (shares) | 14,799 |  |  |  |  |
Special warrant conversion | $ 20,000 | 0 | 0 | 0 | 0 | 20,000
Special warrant conversion (shares) | 16,000 |  |  |  |  |
Warrants exercised | $ 97,400 | 0 | 0 | 0 | 0 | 97,400
Warrants exercised (shares) | 1,948,000 |  |  |  |  |
Shares issued to the University | $ 368,550 | 0 | 0 | 0 | 0 | 368,550
Shares issued to the University (shares) | 63,000 |  |  |  |  |
Share-based compensation | $ 0 | 0 | 0 | 880,615 | 0 | 880,615
Net loss | 0 | 0 | 0 | 0 | (8,650,763) | (8,650,763)
Balance at Sep. 30, 2021 | $ 27,080,281 | $ (33,684) | $ 0 | $ 1,565,055 | $ (9,209,857) | $ 19,401,795
Balance (shares) at Sep. 30, 2021 | 11,834,361 |  |  |  |  |

X
- Definition The increase (decrease) in equity resulting from the acquisition of of intangible assets. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssets
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase and decrease in equity resulting from acquisition of intangible assets shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughAcquisitionOfIntangibleAssetsShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase decrease in equity through settlement of debt with shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughDebtSettlementWithShare
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) through debt settlement with share shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughDebtSettlementWithShareShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) through exercise of warrants shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughExerciseOfWarrantsShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The Increase decrease through distribution of broker warrants for finders fees. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughFindersFeesBrokerWarrants
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the increase (decrease) through cash distribution for finder's fee. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughFindersFeesCash
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents increase (decrease) through exercise of options for finders fee. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughFindersFeesShareOptions
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of shares issued under private placement. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughPrivatePlacement
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of shares issued under private placement. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughPrivatePlacementShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) through shares issued to university. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughSharesIssuedToUniversity
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) through shares issued to university shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) through special warrant conversion. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughSpecialWarrantConversion
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) through special warrant conversion shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughSpecialWarrantConversionShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of residual interest in the assets of the entity after deducting all its liabilities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2020-01-01 -Paragraph 24 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_a&doctype=Standard -URIDate 2020-01-01 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2020-01-01 -Paragraph 32 -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_i&doctype=Standard -URIDate 2020-01-01 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2020-01-01 -Paragraph 93 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_a&doctype=Standard -URIDate 2020-01-01 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2020-01-01 -Paragraph 93 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_b&doctype=Standard -URIDate 2020-01-01 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 13 -IssueDate 2020-01-01 -Paragraph 93 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2020-en-r&anchor=para_93_e&doctype=Standard -URIDate 2020-01-01 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_55&doctype=Standard -URIDate 2020-01-01 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 78 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_Equity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The increase (decrease) in equity resulting from the exercise of warrants. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 106 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 106 -Subparagraph d -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 79 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfSharesOutstanding
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2020-01-01 -Paragraph 18 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard -URIDate 2020-01-01 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2020-01-01 -Paragraph 24 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard -URIDate 2020-01-01 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2020-01-01 -Paragraph 32 -Subparagraph a -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard -URIDate 2020-01-01 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2020-01-01 -Paragraph 28 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard -URIDate 2020-01-01 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Note Effective on first application of IFRS 9 -Name IFRS -Number 4 -IssueDate 2020-01-01 -Paragraph 39L -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard -URIDate 2020-01-01 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2020-01-01 -Paragraph 23 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard -URIDate 2020-01-01 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2020-01-01 -Paragraph B10 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2020-01-01 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 106 -Subparagraph d -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard -URIDate 2020-01-01 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Note Effective 2021-01-01 -Name IFRS -Number 17 -IssueDate 2020-01-01 -Paragraph 113 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard -URIDate 2020-01-01 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 81A -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_ProfitLoss
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of cost related to the issuance of shares. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 106 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_ShareIssueRelatedCost
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration